# China NMPA Drug Inspection - Jianli County Tongren Pharmacy - Atorvastatin calcium tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jianli-county-tongren-pharmacy/c056d68e-c872-4672-a44e-87950d4bc4e8
Source feed: China

> China NMPA drug inspection for Jianli County Tongren Pharmacy published July 03, 2020. Drug: Atorvastatin calcium tablets. This document, issued by the Hubei Provincial Medical Products Administration on July 3, 2020, provides an essential cor

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Explanation of Relevant Matters Regarding the "Hubei Province Drug Quality Bulletin (Issue 1, 2020)"
- Company Name: Jianli County Tongren Pharmacy
- Publication Date: 2020-07-03
- Drug Name: Atorvastatin calcium tablets
- Inspection Finding: The batch of drugs was purchased from illegal channels by Tongren Pharmacy in Jianli County and is counterfeit; the labeled manufacturer, Pfizer Pharmaceuticals Ltd., denies that it produced the drugs.
- Action Taken: The Jianli County Market Supervision Administration investigated the matter and the Hubei Provincial Drug Administration issued a quality announcement explaining the findings.
- Summary: This document, issued by the Hubei Provincial Medical Products Administration on July 3, 2020, provides an essential correction to a previous drug quality bulletin regarding Pfizer Pharmaceuticals Co., Ltd. and the Jianli County Tongren Pharmacy. The original bulletin, published on May 8, 2020, identified a batch of Atorvastatin Calcium Tablets (batch number X07585) as substandard. While Pfizer was initially listed as the manufacturer, the company formally denied involvement with this specific batch. Subsequent investigations conducted by the Jianli County Market Supervision Administration revealed that the medication was counterfeit. The investigation determined that Jianli County Tongren Pharmacy had acquired the products through illegal distribution channels rather than authorized suppliers. Operating under the regulatory oversight of the National Medical Products Administration (NMPA), this clarification serves to protect the reputation of the legitimate manufacturer and alert the public to the presence of counterfeit goods. The primary violation identified was the pharmacy's failure to maintain a secure supply chain, resulting in the distribution of fraudulent medicine. The required regulatory action involved the formal reclassification of the product as counterfeit and the public update of the provincial quality records to reflect the results of the investigation. This case underscores the necessity for pharmacies to source medications strictly from verified channels to ensure consumer safety and product authenticity.

Company: https://www.globalkeysolutions.net/companies/jianli-county-tongren-pharmacy/663e044c-2b0e-4eb2-8500-ff5ba4b8ee03